Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Expected to Announce Quarterly Sales of $3.85 Million

Equities analysts expect that Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) will report sales of $3.85 million for the current quarter, according to Zacks. Six analysts have provided estimates for Apellis Pharmaceuticals’ earnings. The highest sales estimate is $10.15 million and the lowest is $1.83 million. Apellis Pharmaceuticals reported sales of $650,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 492.3%. The business is scheduled to report its next quarterly earnings results on Monday, November 1st.

According to Zacks, analysts expect that Apellis Pharmaceuticals will report full year sales of $21.84 million for the current fiscal year, with estimates ranging from $5.12 million to $68.48 million. For the next financial year, analysts anticipate that the business will report sales of $142.02 million, with estimates ranging from $77.04 million to $245.92 million. Zacks’ sales calculations are an average based on a survey of research firms that follow Apellis Pharmaceuticals.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Sunday, August 8th. The company reported ($2.72) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.70) by ($1.02). The company had revenue of $0.62 million during the quarter, compared to analyst estimates of $2.26 million.

Several equities analysts recently issued reports on APLS shares. Roth Capital decreased their price objective on Apellis Pharmaceuticals from $80.00 to $46.00 and set a “buy” rating for the company in a research report on Friday, September 10th. UBS Group assumed coverage on Apellis Pharmaceuticals in a research note on Thursday, May 20th. They issued a “buy” rating and a $82.00 target price on the stock. Credit Suisse Group cut their target price on Apellis Pharmaceuticals from $50.00 to $38.00 and set a “neutral” rating on the stock in a research note on Friday, September 10th. Jefferies Financial Group assumed coverage on Apellis Pharmaceuticals in a research note on Thursday, August 19th. They issued a “buy” rating and a $74.00 target price on the stock. Finally, Robert W. Baird boosted their target price on Apellis Pharmaceuticals from $75.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $70.44.

In related news, insider Pascal Deschatelets sold 6,250 shares of the business’s stock in a transaction that occurred on Thursday, June 24th. The stock was sold at an average price of $65.61, for a total transaction of $410,062.50. Following the transaction, the insider now directly owns 875,837 shares of the company’s stock, valued at approximately $57,463,665.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Alec Machiels sold 2,500 shares of the company’s stock in a transaction on Thursday, July 15th. The shares were sold at an average price of $62.30, for a total value of $155,750.00. Following the completion of the transaction, the director now directly owns 672,044 shares in the company, valued at $41,868,341.20. The disclosure for this sale can be found here. Insiders have sold a total of 11,500 shares of company stock worth $741,873 over the last three months. 9.50% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of APLS. Parametric Portfolio Associates LLC grew its holdings in shares of Apellis Pharmaceuticals by 86.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 57,748 shares of the company’s stock worth $3,650,000 after purchasing an additional 26,858 shares in the last quarter. Integral Health Asset Management LLC acquired a new stake in shares of Apellis Pharmaceuticals during the 2nd quarter worth $2,212,000. Marshall Wace LLP acquired a new stake in shares of Apellis Pharmaceuticals during the 2nd quarter worth $656,000. Morgan Stanley grew its holdings in shares of Apellis Pharmaceuticals by 50.9% during the 2nd quarter. Morgan Stanley now owns 229,341 shares of the company’s stock worth $14,494,000 after purchasing an additional 77,317 shares in the last quarter. Finally, Perceptive Advisors LLC acquired a new stake in shares of Apellis Pharmaceuticals during the 2nd quarter worth $41,785,000. 74.28% of the stock is currently owned by hedge funds and other institutional investors.

Shares of APLS opened at $33.10 on Wednesday. The company has a debt-to-equity ratio of 7.48, a quick ratio of 4.13 and a current ratio of 4.15. The stock has a 50 day simple moving average of $61.76 and a 200 day simple moving average of $54.45. Apellis Pharmaceuticals has a 52-week low of $27.50 and a 52-week high of $73.00. The firm has a market capitalization of $2.88 billion, a PE ratio of -5.62 and a beta of 1.48.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Featured Story: What is a Fibonacci Channel?

Get a free copy of the Zacks research report on Apellis Pharmaceuticals (APLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.